Biotech Values

[DewDiligence]

>> Typical short-term perspective by FDA that played right into the hands of pharma. Characterizing [Authorized Generics] a "pro-competitive business practice" is ridiculous. <<

I can’t tell if the FDA’s decision was deliberately pro-big-pharma or just simpleminded. Is it unthinkable that the bureaucrats’ analysis was as shallow as: uh, duh, more generics must mean more competition… what’s the problem?

If this decision sticks, I predict an FDA-sponsored public hearing in a few years to discuss why there has been a drop-off in the number of generic applications.